Announcements Trials

Browse Landscape

Phase

Status

Enrolling by invitation 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 22 Plasma cell 5 Other hematologic neoplasm 3 Gastrointestinal 3 Myeloid 2 Lymphoid 2 Sarcoma 1 Head & Neck 1 Gynecologic 1 Genitourinary 1 CNS 1

Conditions

Urinary Bladder Neoplasms 1

Interventions

Docetaxel 409 pembrolizumab 331 Prednisone 289 enzalutamide 283 Gemcitabine 274 Radiotherapy 270 Magnetic Resonance Spectroscopy 269 Nivolumab 252 Abiraterone Acetate 217 Cisplatin 212 Leuprolide 195 Radiosurgery 192 Sunitinib 188 Carboplatin 161 Androgen Antagonists 156 bicalutamide 152 Specimen Handling 149 Goserelin 149 Ipilimumab 131 Paclitaxel 126 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 122 apalutamide 117 Cyclophosphamide 117 Bevacizumab 116 Sorafenib 114 Everolimus 111 abiraterone 106 cabozantinib 104 atezolizumab 104 Biopsy 101

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

apixaban × Genitourinary × Clear all

NCT06243510 2026-01-28

CARE

Abramson Cancer Center at Penn Medicine

Phase NA Enrolling by invitation

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡